Lab21 hires cfo
Susan Lowther joins Cambridge, UK-based firm
Lowther has spent more than 20 years in the pharmaceutical, biotech and healthcare industries and has held senior management positions at BioWisdom, RiboTargets, Lonza Biologics, Celltech and Monsanto.
Graham Mullis, Lab21 ceo, said: ‘Susan’s financial and life sciences industry expertise, particularly in the area of acquisitions, will be essential as we continue to develop the company.’
You may also like
Ingredients
![UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny]()
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny
The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Manufacturing
![Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India]()
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India
The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
Pharmaceutical
![OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics]()
OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics
The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, helping laboratories maintain compliant leukaemia and myeloma testing workflows
